How do cherry angiomas differ from infantile (strawberry) hemangiomas in terms of presentation, age of onset, clinical course, and treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cherry Angiomas vs Infantile (Strawberry) Hemangiomas: Key Distinctions

Cherry angiomas and infantile hemangiomas (formerly called "strawberry" hemangiomas) are fundamentally different entities: cherry angiomas are benign vascular proliferations that appear in adults and increase with age, requiring no treatment unless cosmetically desired, while infantile hemangiomas are vascular tumors of infancy that appear in the first weeks of life, undergo rapid growth followed by involution, and may require urgent intervention with propranolol when they threaten function or cause disfigurement.

Age of Onset and Patient Population

Infantile Hemangiomas

  • Appear exclusively in infants during the first weeks or months of life 1
  • Affect 4-10% of infants, making them the most common benign tumor of infancy 1, 2
  • Female predominance (72%) with risk factors including prematurity, low birth weight, and multiple gestations 2
  • 50% have a precursor lesion present at birth 2

Cherry Angiomas

  • Appear in adults, becoming increasingly common with advancing age 3
  • Most prevalent vascular tumor in the general adult population 3
  • No gender predominance or association with birth factors
  • May appear eruptively in rare cases, sometimes associated with hormonal fluctuations 4

Clinical Presentation

Infantile Hemangiomas

The 2019 AAP guidelines clearly define superficial infantile hemangiomas as red lesions with little or no subcutaneous component (the "strawberry" appearance) 1. Key features include:

  • Characteristic growth pattern: rapid proliferation for 4-6 months (most significant growth between 1-3 months), plateau phase, then gradual involution over years 1, 5
  • Growth typically complete by 5 months of age 1
  • Most commonly located on head and neck (42%) 2
  • Can be superficial (red), deep (blue, subcutaneous), or combined 1
  • May leave permanent skin changes even after involution 1

Cherry Angiomas

  • Small, bright red to purple papules that persist indefinitely 3
  • No proliferative or involutive phases
  • Remain stable in size once formed
  • Distributed across trunk and extremities typically
  • Multiple lesions common, increasing in number with age 3

Clinical Course and Natural History

Infantile Hemangiomas

Time-sensitive management is critical because the window of opportunity for optimal treatment occurs during the rapid growth phase (1-3 months of age) 1. The natural history follows three distinct phases:

  1. Proliferative phase (0-5 months): rapid growth
  2. Plateau phase: variable duration
  3. Involution phase: gradual regression over years, though residual changes often persist 5

Cherry Angiomas

  • No growth phases or involution
  • Persist indefinitely once formed
  • Purely cosmetic concern with no functional implications 3
  • Recent evidence suggests possible associations with toxic exposures, medications, or systemic diseases, though clinical significance remains unclear 3

Treatment Approach

Infantile Hemangiomas

Early referral by 1 month of age is recommended for potentially problematic lesions 1. The treatment algorithm depends on risk stratification:

High-risk features requiring intervention:

  • Facial location (risk of permanent scarring/disfigurement)
  • Periorbital location (risk of amblyopia) 2
  • Airway involvement
  • Large segmental lesions (>5 cm)
  • Ulceration
  • Associated syndromes (PHACES, LUMBAR) 5, 2

First-line systemic therapy:

  • Propranolol 2-3 mg/kg/day is the treatment of choice for problematic infantile hemangiomas requiring systemic therapy 1, 5
  • Continue for at least 6 months, often until 12 months of age 1

Alternative treatments:

  • Topical timolol for thin, superficial lesions 1
  • Surgery/laser primarily for residual skin changes after involution 1
  • Pulsed dye laser (PDL) preferred over other modalities when laser indicated 6

Cherry Angiomas

No treatment necessary unless cosmetically desired 3. When treatment requested:

  • Pulsed dye laser (PDL) preferred due to decreased procedure-related pain 7
  • Nd:YAG 1064 nm produces fewer pigmentary complications 7
  • Alternative options: cryotherapy, electrosurgery, sclerotherapy, radiofrequency ablation 7
  • No single modality proven superior 7

Critical Pitfalls to Avoid

Do not confuse terminology: The term "strawberry hemangioma" is outdated and should be replaced with "superficial infantile hemangioma" to avoid confusion with other vascular entities 1. Cherry angiomas are completely unrelated despite both being vascular lesions.

Do not delay referral for infantile hemangiomas: Missing the 1-3 month window for intervention can result in permanent disfigurement that could have been prevented 1. Most infantile hemangiomas are benign and require only observation, but high-risk features demand urgent evaluation.

Do not assume cherry angiomas are always benign markers of aging: While typically insignificant, recent evidence suggests possible associations with systemic conditions, toxic exposures, or medications that may warrant investigation in unusual presentations 3.

References

Research

Clinical Relevance of Cherry Angiomas.

Actas dermo-sifiliograficas, 2023

Research

[Infantile hemangiomas: diagnosis and modern therapeutic approaches].

Dermatologie (Heidelberg, Germany), 2026

Research

Treatment Modalities for Cherry Angiomas: A Systematic Review.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.